FEELM
14.5.2023 17:06:34 CEST | Business Wire | Press release
FEELM launched its new innovative disposable vape solution FEELM Max, at the Vaper Expo UK 2023 in Birmingham on May 13.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230514005039/en/
Johnny Zhang, The Assistant President at FEELM (Photo: Business Wire)
As a leading vaping technology provider and flagship brand of atomization tech company SMOORE, FEELM unveiled the advanced FEELM Max solution which boasts three major breakthroughs: the advanced heating technology of the Ceramic Coil S1, a constant power control system and mindful design.
With the first products featuring the FEELM Max solution about to launch in the UK and EU markets, the launch was attended by many top level representatives from many client companies including BAT, RELX International, Totally Wicked, and KIWI.
Setting New 800-Puff Benchmark for 2 ML E-Liquid
The coil technology journey began with first-generation cotton wick coils, progressed to second-generation cotton mesh coil, and has now developed into the era of third-generation ceramic coil technology with the FEELM Max being the latest manifestation of this industry innovation.
Designed to deliver a superior vaping experience, the innovative FEELM Ceramic Coil S1 brings cutting-edge coil technology that offers an increased puff count, setting a new benchmark in the market.
Benefitting from its cotton-free design and the resulting improvement of e-liquid utilization, the FEELM Max is able to boost puff count by more than 30% compared to cotton coil disposable solutions, providing 800 more puffs and setting a new benchmark for 2ml. This innovation allows products using the FEELM Ceramic Coil S1 to offer increased puff counts while remaining totally compliant with all local regulations.
In addition, the new S1 coil decreases the amount of impurities from the heating process by 78%, resulting in fresher breath and no unpleasant aftertaste. This is a significant stride towards ensuring a clean and silky vaping experience for consumers.
Electronic and Design Breakthroughs
The FEELM Max solution uses a constant power energy management system for stable vaping and over 95% vapor consistency. This technology improves taste consistency by 35%, which further enhances the user experience.
FEELM Max products showcase a transparent e-liquid tank for both aesthetics and user convenience. No longer will vapers have to guess how much e-liquid is left in their device because one quick look will let them know. The CMF Lab refines this design through specialized research and has developed a scientific ergonomic model for the vaping industry.
First Industrial End-To-End Whole-Chain Recycling Scheme
FEELM has also launched the first industrial whole-chain recycling scheme, collaborating with RELX International in the UK. Conscious of the potential harm of vapes ending up in landfills, FEELM has taken the responsibility for implementing a scheme that will facilitate vape recycling to a fuller extent, thereby minimising the environmental impact.
The company's commitment to making recycling more accessible demonstrates its dedication to environmental sustainability. As the initiative gains traction, it could serve as a model for other industries looking to implement eco-friendly practices and engage adult customers in sustainability efforts.
Shaping a Sustainable and Compliant Future with Partners
FEELM's success is not solely due to its innovative technology and the relentless pursuit of excellence, but also the strong collaboration it has forged with its clients and industry partners.
Bing Du, the CEO and founder of RELX International stated at the event: “Thanks to the groundbreaking technology of FEELM Max, and driven by our legendary partnership with FEELM, RELX International is on course to revolutionize the vaping experience across the globe.”
Liam Cagliarini, UK CEO of KIWI Vapor, the leading Italian brand, stated: "We aim to collaborate with FEELM on latest technology, and provide a consistency vaping experience for consumers."
Marcus Saxton, CEO of Totally Wicked, top British brand, added: "FEELM’s innovative technology has enhanced the consumer experience. As a partner of FEELM, Totally Wicked shares the responsibility of promoting sustainability in the atomization industry through active participation in the recycling system."
FEELM intends to continue pushing the boundaries of what's possible in vaping technology, while keeping its commitment to sustainability and compliance at the heart of its operations. The company's mission to shape a better vaping industry, not only for today but for generations to come, remains stronger than ever.
About FEELM
As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.
About SMOORE
Founded in 2009, SMOORE is a global leader in atomization technology solutions, covering reduced-risk products, medical, pharmaceutical, and beauty atomization technologies. With inter-disciplinary atomization research and a diverse product portfolio, SMOORE is committed to becoming an advanced platform, aspired to make life better.
With continuous R&D investment and leading manufacturing capacity, SMOORE has 14 technology research centers worldwide and products are available in more than 50 countries and regions. SMOORE announced IPO in Hong Kong on July 10, 2020.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230514005039/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom